Alexion Pharmaceuticals systematic to reduce cost of Soliris in Canada

Soliris treats dual singular diseases where a body’s defence complement attacks and destroys red blood cells. In Canada, a drug costs about $700,000 per studious per year. (Kelly Crowe/CBC)

Canada’s drug cost watchdog has systematic Alexion Pharmaceuticals to reduce a cost of Soliris, one of a world’s many costly drugs. 

In a preference expelled Wednesday, the Patented Medicine Prices Review Board ruled that a cost of Soliris (eculizumab) is excessive.

The row has also systematic Alexion to compensate Ottawa behind for overcharging Canadians for a drug. The volume of that additional income has not been disclosed. Soliris can cost some-more than half a million dollars per studious per year in Canada.

• ANALYSIS |  How a curative organisation labelled a life-saving drug during $500K a year
• SECOND OPINION | The tip universe of drug prices
   

The drug treats dual singular diseases where a body’s defence complement attacks and destroys red blood cells. In Canada, Soliris can cost about $700,000 per studious per year, depending on a weight of a patient.

The @PMPRB_CEPMB Hearing Panel has released a preference on a matter relating to Soliris https://t.co/j5n1nAFTR7 #cdnhealth

—
@PMPRB_CEPMB

In a matter to CBC News, Alexion pronounced “we strongly remonstrate with a PMPRB panel’s preference and we will be seeking evident legal review.” 

Article source: http://www.cbc.ca/news/health/solaris-pmprb-1.4310249?cmp=rss